Fusion Pharmaceuticals Inc

NASDAQ:FUSN   3:57:09 PM EDT
2.54
-0.09 (-3.42%)
Other Pre-Announcement

Fusion Pharmaceuticals Provides Updates On FPI-1434 And FPI-1966 Clinical Programs

Published: 06/09/2022 11:42 GMT
Fusion Pharmaceuticals Inc (FUSN) - Fusion Pharmaceuticals- in Fpi-1434 Trial, Expects to Report Phase 1 Safety, Pharmacokinetics, Imaging Data, Details on Dosing Regimen, in H1 2023 .
Fusion Pharmaceuticals Provides Updates on Fpi-1434 and Fpi-1966 Clinical Programs.
Fusion Pharmaceuticals Inc- Also Updating Guidance for Fpi-1966 and Expects to Dose First Patient in This Study in Second Half of 2022.